Molecular Staging for Survival Prediction of Colorectal Cancer Patients
Authors:
- Ivana YangIYIvana Yang
- Greg BloomGBGreg Bloom
- Ka Yin KwongKKKa Yin Kwong
- David BoulwareDBDavid Boulware
- Alan CantorACAlan Cantor
- Domenico CoppolaDCDomenico Coppola
- Mogens KruhøfferMKMogens Kruhøffer
- Lauri AaltonenLALauri Aaltonen
- Torben F. OrntoftTOTorben F. Orntoft
- John QuackenbushJQJohn Quackenbush
- Timothy J. YeatmanTYTimothy J. Yeatman
- 20 May 2005
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (15) , 3526-3535
Abstract
Purpose: The Dukes' staging system is the gold standard for predicting colorectal cancer prognosis; however, accurate classification of intermediate-stage cases is problematic. We hypothesized that molecular fingerprints could provide more accurate staging and potentially assist in directing adjuvant therapy. Methods: A 32,000 cDNA microarray was used to evaluate 78 human colon cancer specimens, and these results were correlated with survival. Molecular classifiers were produced to predict outcome. Results: Molecular staging, based on 43 core genes, was 90% accurate (93% sensitivity, 84% specificity) in predicting 36-month overall survival in 78 patients. This result was significantly better than Dukes' staging (P = .03878), discriminated patients into significantly different groups by survival time (P < .001, log-rank test), and was significantly different from chance (P < .001, 1,000 permutations). Furthermore, the classifier was able to discriminate a survival difference in an independent test set from Denmark. Molecular staging identifies patient prognosis (as represented by 36-month survival) more accurately than the traditional clinical staging, particularly for intermediate Dukes' stage B and C patients. The classifier was based on a core set of 43 genes, including osteopontin and neuregulin, which have biologic significance for this disease. Conclusion: These data support further evaluation of molecular staging to discriminate good from poor prognosis patients, with the potential to direct adjuvant therapy.Keywords
This publication has 18 references indexed in Scilit:
- Multi-Platform, Multi-Site, Microarray-Based Human Tumor ClassificationThe American Journal of Pathology, 2004
- Gene Discovery in Bladder Cancer Progression using cDNA MicroarraysThe American Journal of Pathology, 2003
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Osteopontin Identified as Lead Marker of Colon Cancer Progression, Using Pooled Sample Expression ProfilingJNCI: Journal of the National Cancer Institute, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learningNature Medicine, 2002
- Multiclass cancer diagnosis using tumor gene expression signaturesProceedings of the National Academy of Sciences, 2001
- Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclassesProceedings of the National Academy of Sciences, 2001
- Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networksNature Medicine, 2001
- The classification of cancer of the rectumThe Journal of Pathology and Bacteriology, 1932